Ranibizumab Versus PDT for Presumed Ocular Histoplasmosis

Part of paid clinical trials in Indianapolis, Indiana.

Sponsor
Barnes Retina Institute
Study ID
NCT00546936
Phase
PHASE2
Status
Unknown

Conditions

  • Presumed Ocular Histoplasmosis (POHS)

Eligibility Criteria

Sex
ALL
Age
21 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • ranibizumab — DRUG
    0.5mg ranibizumab
  • verteporfin — DRUG
    Photodynamic therapy with verteporfin every 3 months for 1 year

Study Details

The purpose of this study is to evaluate the change in visual activity of ranibizumab to Photodynamic Therapy (PDT)in patients with choroidal neovascularization (CNV) secondary to presumed ocular histoplasmosis

Key Dates

Start date
Oct 31, 2007
Status verified
Apr 2009
Primary completion
Oct 31, 2009
Completion
Apr 30, 2010

Study Design

Enrollment
30 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: ranibizumab intravitreal injection
    0.5 mg intravitreal injection of ranibizumab
  • Active Comparator: Photodynamic Therapy
    Photodynamic therapy with Visudyne

Primary Outcome Measure

Mean change in visual acuity [ Time Frame: 6 months, 1 year ]

Central Contacts

Locations (2)

FacilityCityStateZIPSite coordinators
Macula-Retina-Vitreous Service, Midwest Eye InstituteIndianapolisIndiana46280
Neelam Thukral
[email protected]
317-805-2152
Thomas Ciulla, MD (PRINCIPAL_INVESTIGATOR)
Barnes Retina InstituteSt LouisMissouri63110
Ginny S Nobel, COT
[email protected]
314-367-1278
Carol L Walters, COT
[email protected]
314-367-2287
Kevin J Blinder, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Indianapolis, IN

By research site
Macula-Retina-Vitreous Service, Midwest Eye Institute· Indianapolis, INBarnes Retina Institute· St Louis, MO